ACCESS Newswire

InterAx Biotech AG

10.11.2023 14:02:39 CET | ACCESS Newswire | Press release

Share
InterAx Biotech Announces Being the Recipient of a Highly Competitive European Grant to Fund Drug Development and Reports Financing Highlights

InterAx Biotech AG, a pharmaceutical product development company pioneering computational pharmacology for drug discovery, announces being awarded a highly competitive and prestigious grant to apply its drug discovery and development platform to the breakthrough technology programs sponsored by the EU commission.

ZURICH, SWITZERLAND / ACCESSWIRE / November 10, 2023 / The total volume of the Horizon Europe EIC Pathfinder project is EUR 3.7M, which is split among project participants. In this consortium, InterAx has secured more than 700k. The goals of the consortium are to implement innovative methods for characterizing the intracellular functions of drug candidates, a critical component in the selection process of lead compounds. A key objective is to generate high-quality datasets to train AI algorithms to elucidate biological responses. Each participant provides their own unique and complimentary sets of skills and technology to the overall program. InterAx was selected following review by a panel of experts, recognizing the pioneering use of mathematical models and AI in developing drugs with targeted cellular effects as crucial to the program's success.

Dr. Aurélien Rizk, Chief Scientific Officer stated, "the reviewers acknowledged our development of a cutting-edge, computer-aided drug discovery platform. It excels in decoding intricate intracellular biological responses, identifying ideal cellular effects that maximize efficacy while minimizing side effects and designing novel drugs accordingly."

Dr. Chris Prior, Chief Executive Officer noted, "We are delighted that we have been selected for a highly competitive European grant which has an historical success rate of about 4%. This is tremendous peer review validation to the credit of the InterAx multidisciplinary team of scientists with expertise in organic and computational chemistry, biophysics, molecular biology, pharmacology, mathematics and Artificial Intelligence. Dr. Prior added, "This award greatly complements our financing needs as well as adding significant validation in support of fundraising efforts and discussions with partners. We are also very pleased with the strong support of our investors in a recent financing. The proceeds will advance our in-house two lead programs in cancer and inflammation towards IND and this will prepare us for the next stage of financing."

InterAx Biotech AG

The company, a spin-out from ETH Zurich and the Paul Scherrer Institute in Switzerland, developed an integrated drug discovery process combining biochemical compound screening, cell pathways mathematical modeling, and Artificial Intelligence based chemical structure to function relationship. This unique approach enables the rapid and precise identification of novel cellular mechanisms to develop differentiated products that stand out for their effectiveness and safety profiles. This platform unlocks previously intractable targets, shortens timelines for drug discovery from years to months and reduces risks.

The company is specialized in G Protein-Coupled Receptor (GPCR) drug discovery and covers hit-generation, hit-to-lead and lead optimization for all targets including orphan GPCRs. InterAx has a highly experienced and dedicated team of scientists specialized in AI, mathematical models of signaling pathways, cellular pharmacology and computational chemistry. The company is currently funded by lead institutional investors and a grant from the EU commission and is preparing for the next round of financing to grow its capabilities and advance lead drug candidates.

For more information, please visit linkedin.com/company/interax-biotech | www.interaxbiotech.com

Media contact: Luca Zenone, contact@interaxbiotech.com

SOURCE: InterAx Biotech AG



View source version on accesswire.com:
https://www.accesswire.com/801619/interax-biotech-announces-being-the-recipient-of-a-highly-competitive-european-grant-to-fund-drug-development-and-reports-financing-highlights

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Kontent.ai Appoints Mark Greenaway as CEO to Drive the Next Phase of AI in Enterprise Content27.4.2026 08:00:00 CEST | Press release

BRNO, CZ / ACCESS Newswire / April 27, 2026 / Kontent.ai has appointed Mark Greenaway as Chief Executive Officer, as the company looks to scale its Agentic CMS and transform content operations for customers. Greenaway brings a track record of scaling businesses and leading high performing global teams with a focus on enterprise environments where content is both a marketing asset and a critical driver of growth, compliance, and customer experience. With this appointment, Kontent.ai founder Petr Palas returns to his position on the board at Kontent.ai and will continue to support the business he launched in 2022 as a successful spin out of Kentico. Kontent.ai recently launched their next generation of "Agentic CMS" with the launch of Expert Agents. These Agents are embedded directly into workflows to continuously handle operational tasks such as governance, search and generation engine (LLM) optimization, translation, and lifecycle management, work that typically requires significant ma

HrFlow.ai Secures 7 Million Dollars (Pre-Series A) to Become the Global Standard for Artificial Intelligence (AI) Applied to HR Data24.4.2026 01:40:00 CEST | Press release

PARIS, FR / ACCESS Newswire / April 23, 2026 / 1. Fundraising and Objectives HrFlow.ai, a pioneer in Artificial Intelligence applied to Human Resources data, announces its second fundraising round of $7M (pre-Series A) today. This financing brings the company's total capital raised to $10 million. This new capital injection is designed to accelerate the company's core mission: building the Data & AI infrastructure of the labor market. The round is led by 115K, La Banque Postale's venture capital fund, and EmergingTech Ventures (EmTech), alongside the company's existing investors including Xavier Niel (Free, Kima, Station F), Jean-Baptiste Rudelle (Criteo), Romain Niccoli (Pigment, Criteo), Franck Le Ouay (LIFEN, Criteo), Flavien Kulawik (KLB), Allen Penn (Uber), Dominique Vidal (Index Ventures), Thibaud Elzière (Hexa, Fotolia). Building on rigorous execution and proven capital efficiency since its first funding round of $2.3M in 2018, HrFlow.ai now generates a margin of approximately 2

Datavault AI Further Expands IP Portfolio with New Patent Issuance and Notices of Allowance22.4.2026 16:00:00 CEST | Press release

Builds on December 2025 Content Licensing Patents and Carbon Credit Tokenization Grant; Strengthens IP Moat Across Data Valuation, Virtual Funding, and Tokenized Tax Prep PHILADELPHIA, PA / ACCESS Newswire / April 22, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a leader in AI-driven data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, today announced the issuance of U.S. Patent No. 12,596,819 and Notices of Allowance on two additional U.S. patent applications. This milestone builds directly on the Company's December 2025 issuance of two foundational patents for blockchain-driven content licensing and tokenized monetization - further expanding its robust intellectual property portfolio headlined by the industry-defining Carbon Credit Tokenization Patent. Key Highlights for Investors One newly issued patent and two Notices of Allowance extend protection across three high-value platforms: AI-validated d

Karbon-X Highlights SkyXero on Earth Day, Bringing Real-Time Climate Action to Travel22.4.2026 15:15:00 CEST | Press release

Company underscores leadership use and introduces matched contribution initiative to support verified climate projects. CALGARY, AB / ACCESS Newswire / April 22, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions provider operating across compliance and voluntary carbon markets, today marked Earth Day by highlighting SkyXero, its mobile application designed to help individuals understand and act on the emissions associated with their air travel. As global travel continues to increase, flight emissions remain one of the least visible and least understood components of individual environmental impact. SkyXero addresses this gap by enabling users to calculate emissions associated with any commercial flight and support verified climate projects such as reforestation, renewable energy, and carbon reduction initiatives. To reinforce its commitment to practical climate accountability, Karbon-X has applied SkyXero internally across its l

DOJO AI Raises $6M to Power Agentic Marketing Platform, Transforming Data Into Business Impact22.4.2026 14:00:00 CEST | Press release

Backed by Armilar and Heartfelt VC, the company serves over 100 customers across the U.S. and U.K., including CoinDesk, Morningstar, Broadvoice, PensionBee, CovertSwarm and Refine Labs LONDON, UK AND LISBON, PORTUGAL / ACCESS Newswire / April 22, 2026 / DOJO AI, the intelligent marketing system that brings a new class of integrated AI to marketing teams, today announced a $6 million seed round at a $30 million valuation. The round was led by Armilar, with participation from Heartfelt VC. The funding will support continued product development and accelerated expansion in the United States. DOJO AI introduces a new paradigm for marketing technology, powering what the industry is beginning to call agentic marketing: a system where AI agents don't just report on performance but take action on it. The platform watches paid and organic campaigns around the clock, audits SEO and Answer Engine Optimization visibility continuously, generates brand-aligned content, and feeds every outcome back i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye